Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.

Breast cancer research and treatment - 1 Dec 2016

Graffeo Rossella, Livraghi Luca, Pagani Olivia, Goldhirsch Aron, Partridge Ann H, Garber Judy E

Abstract excerpt

PURPOSE: Genetic evaluation is increasingly becoming an integral part of the management of women with newly diagnosed breast and ovarian cancer (OC), and of individuals at high risk for these diseases. Genetic counseling and testing have been incorporated into oncological care to help and complete management and treatment strategies. Risk assessment and early detection strategies in individuals with BRCA1/2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms, Male
Share to Disease Management

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fanconi Anemia Complementation Group N Protein

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Hereditary Breast and Ovarian Cancer Syndrome

Share to Penetrance

Share to Stomach Neoplasms

Source

Identifiers

PMID: 27734215
DOI: 10.1007/s10549-016-4003-9

Genes

ATM
BRCA1
BRIP1
CDH1
CHEK2
PALB2
PTEN
STK11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.PMID 27734215Read ↗

Comprehensive Clinical Genetics, Molecular and Pathological Evaluation Efficiently Assist Diagnostics and Therapy Selection in Breast Cancer Patients with Hereditary Genetic Background.Semantic proximity Read ↗

Breast cancer multigene germline panel testing in mainstream oncology based on clinical-public health utility (cancer mortality benefit): ESMO Precision Oncology Working Group recommendationsSemantic proximity Read ↗

Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?Semantic proximity Read ↗

Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working GroupSemantic proximity Read ↗

Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.Semantic proximity Read ↗

A new paradigm of genetic testing for hereditary breast/ovarian cancers.Semantic proximity Read ↗

Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic OutcomesSemantic proximity Read ↗

Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.Semantic proximity Read ↗

Breast cancer germline multigene panel testing in mainstream oncology based on clinical–public health utility: ESMO Precision Oncology Working Group recommendationsSemantic proximity Read ↗

Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.Semantic proximity Read ↗

Impact of non-BRCA genes in the indication of risk-reducing surgery in hereditary breast and ovarian cancer syndrome (HBOC).Semantic proximity Read ↗

The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.